A Study of Brenipatide in Adult Participants With Major Depressive Disorder
← catalyst calendarNCT07412756 · readout ≤ 559 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,000estimated
Sites
179
Countries
Australia, Brazil, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-09 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Depressive Disorder, Major
Interventions
- Drug: Brenipatide — also filed as LY3537031
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD)
measured From Randomization in Double-Blind Adjunctive Treatment to First Relapse For at Least 12 Months
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed